FUDA, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 3.571
EU - Europa 2.017
AS - Asia 1.887
SA - Sud America 259
Continente sconosciuto - Info sul continente non disponibili 135
AF - Africa 44
OC - Oceania 13
Totale 7.926
Nazione #
US - Stati Uniti d'America 3.403
IT - Italia 774
SG - Singapore 671
CN - Cina 530
DE - Germania 297
VN - Vietnam 240
BR - Brasile 191
FR - Francia 156
IE - Irlanda 146
SE - Svezia 123
FI - Finlandia 120
GB - Regno Unito 106
CA - Canada 104
AT - Austria 68
IN - India 65
JP - Giappone 65
KR - Corea 65
HK - Hong Kong 64
BD - Bangladesh 61
UA - Ucraina 53
PL - Polonia 42
NL - Olanda 35
AR - Argentina 27
ID - Indonesia 25
MX - Messico 23
ZA - Sudafrica 15
BE - Belgio 14
CL - Cile 14
ES - Italia 14
TR - Turchia 12
RU - Federazione Russa 11
UZ - Uzbekistan 11
EC - Ecuador 10
JM - Giamaica 10
AU - Australia 9
IQ - Iraq 9
PH - Filippine 9
TN - Tunisia 9
TW - Taiwan 9
CH - Svizzera 8
CO - Colombia 7
CR - Costa Rica 7
SN - Senegal 7
GR - Grecia 6
RO - Romania 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
GT - Guatemala 5
IL - Israele 5
IR - Iran 5
SI - Slovenia 5
TH - Thailandia 5
KZ - Kazakistan 4
PK - Pakistan 4
SA - Arabia Saudita 4
VE - Venezuela 4
EU - Europa 3
HR - Croazia 3
HU - Ungheria 3
JO - Giordania 3
MA - Marocco 3
MD - Moldavia 3
NI - Nicaragua 3
NO - Norvegia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PS - Palestinian Territory 3
PT - Portogallo 3
PY - Paraguay 3
RS - Serbia 3
BB - Barbados 2
BG - Bulgaria 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
LU - Lussemburgo 2
MK - Macedonia 2
MY - Malesia 2
PE - Perù 2
TC - Turks e Caicos 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
KW - Kuwait 1
LB - Libano 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
PW - Palau 1
SR - Suriname 1
VC - Saint Vincent e Grenadine 1
Totale 7.797
Città #
Ashburn 412
Singapore 349
San Jose 258
Chandler 244
Beijing 215
Santa Clara 177
Dublin 146
Torino 130
Fairfield 128
Turin 113
Houston 102
Ann Arbor 78
Milan 73
Dallas 70
Woodbridge 63
Ho Chi Minh City 59
Council Bluffs 58
Hanoi 57
Wilmington 55
Los Angeles 54
Rome 54
Hong Kong 53
Vienna 53
Villeurbanne 51
Seattle 50
Munich 49
New York 47
Toronto 46
Columbus 45
Hefei 43
Lauterbourg 40
Nyköping 40
Redwood City 40
Seoul 40
Jacksonville 39
Cambridge 38
Fremont 35
Warsaw 35
Helsinki 33
Princeton 33
Buffalo 32
Medford 32
Pisa 32
São Paulo 30
Tokyo 30
The Dalles 28
Dearborn 24
Dong Ket 24
Phoenix 21
Guangzhou 20
Turku 20
London 19
Bengaluru 18
Lappeenranta 18
Orem 17
Boston 16
Chicago 16
Haiphong 16
Jakarta 16
Shanghai 16
Nuremberg 15
Paris 15
Washington 15
Denver 14
Nürnberg 14
Brussels 13
Da Nang 13
Düsseldorf 13
Amsterdam 12
Atlanta 12
Bologna 12
Collegno 12
Frankfurt am Main 12
Waterloo 12
Boardman 11
Naples 11
Santiago 11
Bochum 10
Johannesburg 10
Mexico City 10
Montreal 10
San Diego 10
Mumbai 9
Palermo 9
Curitiba 8
Hangzhou 8
Norwalk 8
San Francisco 8
Taipei 8
Brooklyn 7
Chengdu 7
Redondo Beach 7
Stockholm 7
Verona 7
Belo Horizonte 6
Cleveland 6
Figino 6
Kingston 6
San José 6
San Mauro Torinese 6
Totale 4.546
Nome #
A20 in Multiple Sclerosis and Parkinson’s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways? 641
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy 423
Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis 364
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry 339
ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion 285
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients 263
NOX2 in the hSOD1G93A Transgenic Swine: a preliminary overview 253
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial) 236
Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study 216
NADPH oxidase (NOX2) activity is a modifier of survival in ALS 198
Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome? 195
The transcription factor Nurr1 is up-regulated in Amyotrophic Lateral Sclerosis patients and SOD1-G93A mice 187
ALS Clinical Trials: Do the Enrolled Patients Represent the ALS Population? 181
ALS clinical trials: Do enrolled patients accurately represent the ALS population? 178
Genetic counselling in ALS: facts, uncertainties and clinical suggestions 176
HFE p.H63D polymorphism does not influence ALS phenotype and survival 174
Association of Variants in the SPTLC1 Gene with Juvenile Amyotrophic Lateral Sclerosis 168
Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995-2018): Results From the Piemonte and Valle d'Aosta Registry 167
A novel splice site FUS mutation in a familial ALS case: effects on protein expression 163
Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study 161
NADPH oxidase (NOX2) activity is a modifier of survival in ALS. 156
Presymptomatic geographical distribution of ALS patients suggests the involvement of environmental factors in the disease pathogenesis 155
Crostacei Decapodi dell'infralitorale della Calabria jonica 155
NADPH oxidases (NOX) enzymes induced oxidative stress in CIDP patients 152
Brain Metabolic Features of FUS-ALS: A 2-[18F]FDG-PET Study 148
Role of NOX2 enzyme activity in neuroinflammation: preliminary results in Amyotrophic Lateral Sclerosis and Parkinson’s disease 147
Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience 147
Amyotrophic lateral sclerosis caregiver burden and patients’ quality of life during COVID-19 pandemic 146
Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis 142
UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study 139
The role of peripheral immunity in ALS: a population-based study 138
Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers 135
Role of NOX2 enzyme activity in neuroinflammation: preliminary results in Amyotrophic Lateral Sclerosis and Parkinson’s disease 132
NADPH oxidases 2 activation in patients with Parkinson's disease 129
Giving Breath to Motor Neurons: Noninvasive Mechanical Ventilation Slows Disease Progression in Amyotrophic Lateral Sclerosis 125
Disentangling the relationship between social cognition, executive functions and behaviour changes in amyotrophic lateral sclerosis 125
Brain 18fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with TARDBP mutations 117
Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis 111
Tailoring patients’ enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs 110
Phenotype Analysis of Fused in Sarcoma Mutations in Amyotrophic Lateral Sclerosis 95
Brain metabolic connectivity in ALS due to C9ORF72 hexanucleotide expansion: a [18F]FDG-PET study 81
Shared and Unique Disease Pathways in Amyotrophic Lateral Sclerosis and Parkinson's Disease Unveiled in Peripheral Blood Mononuclear Cells 79
Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol 68
Genetic Variants Associated With Neurodegenerative Disorders in Patients With Amyotrophic Lateral Sclerosis and Phenotypic Variability 26
Totale 7.926
Categoria #
all - tutte 24.458
article - articoli 0
book - libri 0
conference - conferenze 2.973
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.431


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022431 0 0 0 63 15 35 32 30 14 51 121 70
2022/2023726 85 65 21 62 73 170 47 30 104 13 30 26
2023/2024412 56 71 28 20 24 38 37 35 3 30 31 39
2024/20251.118 17 77 46 93 237 75 31 45 177 62 99 159
2025/20262.548 268 149 176 250 219 80 402 96 176 219 149 364
2026/2027559 130 151 159 119 0 0 0 0 0 0 0 0
Totale 7.926